HFA Cardio Talk

HFA Cardio Talk

By European Society of CardiologyMedicineHealth & FitnessEducationSelf-Improvement
Download on the App Store

HFA Cardio Talk episodes

  • Management of LVAD in patients with advanced heart failure

    With Justyna Sokolska, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw - Poland, and Maja Cikes, University of Zagreb School of Medicine, Head at the Unit for Heart Failure and Mechanical Circulatory Support, Department of Cardiovascular Diseases, University Hospital Center, Zagreb - Croatia.

    In this episode of HFA CardioTalk, Justyna Sokolska interviews Maja Cikes on the challenges in management of long-term left ventricular assist device in patients with advanced heart failure. The discussion emphasizes the importance of selecting appropriate patients at the optimal time, examines the adverse events and highlights major ongoing clinical trials.

    Recommended readings:

    Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial, Mehra MR, et al. JAMA. 2023 Dec 12;330(22):2171-81

    Trends and Outcomes of Left Ventricular Assist Device Therapy: JACC Focus Seminar, Varshney AS, et al. J Am Coll Cardiol 2022 Mar 22;79(11):1092-1107

    Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry, Cikes M, et al. Eur J Heart Fail 2019 Sep;21(9):1129-41

    A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report, Mehra MR, et al. N Engl J Med 2019 Apr 25;380(17):1618-27

    This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

    23 min
  • Inequalities in heart failure: sex, socioeconomic status, and ethnicity

    With Robert M.A. van der Boon, Erasmus Medical Center, Rotterdam - The Netherlands, and Anuradha Lala, Mount Sinai Fuster Heart Hospital, New York City - USA.

    In this episode of HFA Cardio talk, we dive into how factors like sex, socio-economics status and ethnicity shape the way heart failure presents and progresses in different populations. We'll discuss why recognizing these differences is critical for accurate diagnosis and effective treatment and highlight practical steps clinicians can take to close the gaps in prevention and care.

    Papers:

    https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2534

    https://academic.oup.com/eurheartj/article/40/47/3859/5652224?login=true

    https://www.sciencedirect.com/science/article/pii/S1071916421004322?via%3Dihub

    https://www.sciencedirect.com/science/article/pii/S0002914922010074?via%3Dihub

    https://www.sciencedirect.com/science/article/pii/S2468266719301082?via%3Dihub

    https://journals.lww.com/co-cardiology/fulltext/2021/05000/racial_and_ethnic_disparities_in_heart_failure_.12.aspx

    https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14986

    This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

    17 min
  • Rapid up-titration of GDMT in heart failure

    With Henrique Arfsten, Medical University of Vienna, Vienna - Austria and Alexandre Mebazza, Hospital Lariboisiere, Paris - France.

    In this episode of HFA CardioTalk, Henrike Arfsten and Alexandre Mebazaa discuss the importance of rapid initiation and titration of guideline-directed medical heart failure therapy.

    A focus will be on data from the STRONG-HF trial, which demonstrated safety and efficacy of rapid up-titration following an acute heart failure event. The trial was even stopped early as the benefits of the intensive treatment strategy were overwhelming. Moreover, specific questions are raised, such as the right time to start therapy and how to deal with possible side effects.

    Mebazaa A, et al. Lancet 2022 Dec 3;400(10367):1938-52

    Biegus J, et al. Heart Fail Rev 2024 Sep;29(5):1065-1077

    McDonagh TA, et al. Eur J Heart Fail 2022 Jan;24(1):4-131

    McDonagh TA, et al. Eur J Heart Fail 2024 Jan;26(1):5-17

    This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

    18 min
  • Obesity in Heart Failure

    With Novi Yanti Sari, Siloam Hospitals, Jakarta - Indonesia, and Mark Petrie, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow - UK.

    In this episode of the HFA podcast series, we explore the complex relationship between obesity and heart failure, discussing challenges, management strategies, and the latest therapies, while emphasising the importance of integrated care in improving clinical outcomes.

    This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

    17 min
  • Invasive Monitoring in Heart Failure

    With Jasper Brugts, Erasmus Medical Center Rotterdam, Rotterdam - The Netherlands and Floran Sahiti, University Hospital Würzburg and Comprehensive Heart Failure Center Würzburg, Würzburg - Germany.

    In this episode of the HFA Podcast Series, we will discuss telemonitoring in general, with a main focus on invasive monitoring in heart failure, the current evidence, and the advantages and disadvantages of the systems.

    This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of unrestricted financial support. The discussion has not been influenced in any way by its sponsors.

    21 min
  • Understanding revascularization in heart failure: why, for whom, and when

    With Daniella Motta da Costa Dan, University of São Paulo - Brazil, and Marianna Adamo, University of Brescia - Italy.

    In this episode of HFA CardioTalk, Daniella Motta interviews Marianna Adamo on the controversies, consensus, and challenges surrounding revascularization in ischemic heart failure. The discussion highlights major clinical trials, emphasizes the importance of selecting appropriate patients, and examines the risks and benefits of revascularization in this context. Lastly, they address key updates from the latest ESC guidelines

    This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

    18 min
  • Heart Failure in Pregnancy: Peripartum Cardiomyopathy

    With Emmanouil Kampanieris, University General Hospital of Heraklion, Heraklion - Greece, and Peter Van Der Meer, University Medical Centre Groningen, Groningen - The Netherlands.

    In this episode, Peter Van Der Meer and Emmanouil Kampanieris discuss peripartum cardiomyopathy, a potentially life-threatening condition that presents as heart failure with reduced ejection fraction in women in the last month of pregnancy or in the months after delivery, after other causes of heart failure have been excluded.

    Peripartum Cardiomyopathy is defined as cardiomyopathy occurring towards the end of pregnancy or in the months following delivery with a left ventricular (LV) ejection fraction (EF) 1. Its incidence differs widely depending on the geographic area being higher in developing countries, as 1:100 pregnancies in Nigeria, while in developed countries being lower, as 1:1500 pregnancies in Germany1. Several risk factors have been associated with Peripartum Cardiomyopathy, as pre-eclampsia and many more2. More than half of the affected individuals receiving the appropriate treatment for heart failure have a full recovery in 6 months3. The role of bromocriptine as a potential specific treatment for Peripartum Cardiomyopathy remains uncertain and randomized clinical trials are needed for determining its benefits and safety 2,4. Women willing to have a subsequent pregnancy should be counseled and monitored by a multidisciplinary team experienced with Peripartum Cardiomyopathy3.

    References:

    1. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.

    2. Peripartum Cardiomyopathy: JACC State-of-the-Art Review

    3. Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

    4. Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry

    This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

    17 min
  • Controversies in ICD/CRT implantation in non-ischemic cardiomyopathy for primary prevention

    With Nicolas Verheyen, Medical University of Graz, Graz - Austria, and Lars Kober, Rigshospitalet, Copenhagen University Hospital, Copenhagen - Denmark.

    In this episode of HFA CardioTalk, Nicolas Verheyen interviews Lars Kober on controversies in ICD/CRT implantation in non-ischemic cardiomyopathy for primary prevention. They focus in particular on the importance of selecting the right patients, and discuss biomarkers beyond left ventricular ejection fraction that may add value in predicting sudden death risk, and the need of randomized controlled trials with adequate endpoint selection to guide prophylactic ICD implantation.

    Related scientific paper:

    • 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
    • 2023 ESC Guidelines for the management of cardiomyopathies
    • Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure
    • 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)

    This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

    15 min
  • Heart Failure clinical trials from ESC Congress 2024

    With Jozine ter Maaten, University Medical Center Groningen - The Netherlands, Antonio Cannata, King's College London - UK, Mateusz Sokolski, Wroclaw Medical University - Poland, Henrike Arfsten, Medical University of Vienna - Austria, Stefan Anker, Charité University Hospital Berlin - Germany, Muthiuh Vaduganathan, Brigham and Women's hospital, Harvard Medical School Boston - USA, Cornelia Margineanu, Bucharest – Romania and Kengo Kusano, National Cerebral and Cardiovascular Center Hospital, Osaka - Japan.

    In this multivoice podcast from the ESC Congress 2024, the main results of three randomized controlled clinical trials (FINEARTS-HF, RESHAPE-HF2, and CRABL-HF) are discussed.

    Links to the papers:

    FINEARTS-HF

    RESHAPE-HF2

    This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

    25 min
  • Worsening Heart Failure: Definition, Management, and Outcomes

    With Guillaume Baudry, University Hospital of Brabois, Nancy - France, and Marco Metra, University of Brescia - Italy.

    In this episode of the HFA Cardiotalk podcast, Guillaume Baudry interviews Marco Metra, the lead author of the recent HFA clinical consensus statement on worsening heart failure. They delve into the definition of worsening heart failure, its prognosis, prevention strategies, and both acute and long-term management of this condition.

    Related scientific paper:

    • Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
    • Risk of readmission and death after hospitalization for worsening heart failure: Role of post-discharge follow-up visits in a real-world study from the Grand Est Region of France
    • Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
    • Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
    • Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
    • Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
    • Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

    This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

    23 min

About HFA Cardio Talk

From the publisher's feed

The HFA Cardio Talk provides the opportunity to anyone interested in Heart Failure to receive updates in the field with very specific and diverse topics, go on a deeper subject of an HFA course and to listen to a discussion of key opinion leaders with junior HF specialists. Each month, a new episode lasting approximately 15 minutes and taking the form of a conversation between a member of the HFA Young community and an internationally renowned expert is released.

More shows like HFA Cardio Talk

JACC This Week by American College of Cardiology

JACC This Week

163 Listeners

Heart Podcast by BMJ Group

Heart Podcast

40 Listeners

This Week in Cardiology by Medscape

This Week in Cardiology

893 Listeners

Circulation on the Run by Circulation, an American Heart Association Journal

Circulation on the Run

31 Listeners

Eagle's Eye View: Your Weekly CV Update From ACC.org by American College of Cardiology

Eagle's Eye View: Your Weekly CV Update From ACC.org

135 Listeners

Core IM | Internal Medicine Podcast by Core IM Team

Core IM | Internal Medicine Podcast

1,197 Listeners

השבוע - פודקאסט הארץ by הארץ

השבוע - פודקאסט הארץ

184 Listeners

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research by American College of Cardiology

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

64 Listeners

ESC Cardio Talk by European Society of Cardiology

ESC Cardio Talk

17 Listeners

Cardionerds: A Cardiology Podcast by CardioNerds

Cardionerds: A Cardiology Podcast

438 Listeners

Mayo Clinic Cardiovascular CME by Mayo Clinic

Mayo Clinic Cardiovascular CME

32 Listeners

EHRA Cardio Talk by European Society of Cardiology

EHRA Cardio Talk

4 Listeners

ESC TV Today – Your Cardiovascular News by European Society of Cardiology

ESC TV Today – Your Cardiovascular News

8 Listeners

Heart Rhythm TV Podcast by Heart Rhythm TV

Heart Rhythm TV Podcast

0 Listeners